Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2020HematologyOpen Access

Chemotherapy-free frontline therapy for CLL: is it worth it?

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJoanna RhodesRutgers, The State University of New JerseyJBJacqueline C. BarrientosHofstra University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rhodes et al. (2020) studied this question.

synapsesocial.com/papers/6a9f5e135a8b0dbb8a04ed6ahttps://doi.org/10.1182/hematology.2020000085
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic Significance Of Cytogenetic Complexity and Del(17p) At Diagnosis Of Chronic Lymphocytic Leukemia (CLL)2013 · 3 citations
  2. 2Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study2019 · 471 citations
  3. 3Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia2019 · 754 citations
  4. 4Ibrutinib and Venetoclax for First-Line Treatment of CLL2019 · 514 citations